{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:12:18Z","timestamp":1761919938411},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jhep.2015.02.018","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T14:50:16Z","timestamp":1424357416000},"page":"30-37","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders"],"prefix":"10.1016","volume":"63","author":[{"given":"Donald","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad H.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Kugelmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Everson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velimir","family":"Luketic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Hennicken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.02.018_b0005","unstructured":"World Health Organization. Hepatitis C key facts. WHO factsheet No. 164 2013."},{"key":"10.1016\/j.jhep.2015.02.018_b0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.02.018_b0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.02.018_b0020","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at <http:\/\/www.hcvguidelines.org\/> [accessed 01.10.14]."},{"key":"10.1016\/j.jhep.2015.02.018_b0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.02.018_b0030","first-page":"S397","volume":"8","author":"Reddy","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.02.018_b0035","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1016\/S0168-8278(14)61486-0","article-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin in treatment-na\u00efve or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial","volume":"60","author":"Moreno","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.02.018_b0040","unstructured":"Food and drug administration. SOVALDI\u2122 (Sofosbuvir) prescribing information 2014."},{"key":"10.1016\/j.jhep.2015.02.018_b0045","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.02.018_b0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","article-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","volume":"3","author":"Gao","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2015.02.018_b0060","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.02.018_b0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.02.018_b0075","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1053\/j.gastro.2009.01.039","article-title":"Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa\/ribavirin therapy","volume":"136","author":"Poynard","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.02.018_b0080","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-150-8-200904210-00007","article-title":"Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial","volume":"150","author":"Jensen","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.02.018_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.02.018_b0095","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0168-8278(14)61323-4","article-title":"All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 in treatment-naive patients with chronic HCV genotype 4 infection","volume":"60","author":"Hassanein","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.02.018_b0100","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(14)60060-X","article-title":"Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450\/r+ABT-267 with or without ribavirin in patients with HCV genotype 4 infection","volume":"60","author":"Hezode","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.02.018_b0105","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3851\/IMP2660","article-title":"Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C","volume":"18","author":"Bronowicki","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.02.018_b0110","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.02.018_b0115","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.02.018_b0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.02.018_b0135","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0140","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-Ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0145","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.02.018_b0150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T21:24:07Z","timestamp":1537824247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0168827815001257"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.02.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}